2024 ESMO｜肺癌领域重磅II/III期研究前瞻！

摘要号及标题：

1241MO - III期LAURA研究中枢神经系统和远处进展分析：不可切除的III期EGFR突变NSCLC在根治性放化疗后接受奥希替尼治疗的疗效

1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study

讲者：陆舜（上海市胸科医院陆舜教授）

讲座时间：2024.9.16 14:45 - 14:50

摘要号及标题：

1254MO - Zipalertinib在既往接受过Amivantamab治疗的EGFR外显子20插入（ex20ins）突变NSCLC患者中的安全性和抗肿瘤活性研究

1254MO - Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab

讲者：Antonio Passaro (Milan, Italy)

讲座时间：2024.9.14 10:15 - 10:20

摘要号及标题：

1258MO - NVALT-30研究预设期中分析结果：低剂量 vs. 标准剂量帕博利珠单抗治疗晚期NSCLC

1258MO - Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial

讲者：Michel Van den Heuvel (Nijmegen, Netherlands)

讲座时间：2024.9.14 10:50 - 11:00

摘要号及标题：

1786O - BMS-986012（抗岩藻糖基单唾液酸神经节苷脂-1 [fuc-GM1]）与卡铂+依托泊苷+纳武利尤单抗一线治疗ES-SCLC的随机II期研究的期中分析

1786O - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study

讲者：Ewa Kalinka (Łódź, Poland)

讲座时间：2024.9.13 14:35 - 14:45

摘要号及标题：

LBA48 - CCTG BR.31研究：度伐利尤单抗辅助治疗完全切除NSCLC的全球、双盲、安慰剂对照、随机III期试验

LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small-cell lung cancer (NSCLC)

讲者：Glenwood Goss (Ottawa, Canada, Ontario)

讲座时间：2024.9.13 14:00 - 14:10

摘要号及标题：

LBA49 - AEGEAN研究的拓展性分析：可切除NSCLC新辅助治疗中ctDNA清除率与患者病理缓解和无事件生存（EFS）之间的关联性研究

LBA49 - Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN NSCLC

讲者：Martin Reck (Grosshansdorf, Germany)

讲座时间：2024.9.15 10:40 - 10:45

摘要号及标题：

LBA50 - CheckMate 77T III期研究：可切除NSCLC围手术期应用纳武利尤单抗 vs. 安慰剂的疗效对比

LBA50 - Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: clinical update from the phase 3 CheckMate 77T study

讲者：Jonathan D. Spicer (Montreal, Canada)

讲座时间：2024.9.15 10:15 - 10:20

摘要号及标题：

LBA52 - II期随机、开放标签平台研究GALAXIES Lung-201中期分析：Belrestotug联合Dostarlimab治疗初治局部晚期/转移性、PD-L1高表达（TPS≥50%）的NSCLC患者

LBA52 - Interim Analysis of GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients (pts) With Previously Untreated Locally Advanced/Metastatic (LA/M) PD-L1 High (TPS >/=50%) Non-Small Cell Lung Cancer (NSCLC)

讲者：David R Spigel (Nashville, United States of America, TN)

讲座时间：2024.9.14 08:30 - 08:40

摘要号及标题：

LBA53 - II期RELATIVITY-104研究：纳武利尤单抗+Relatlimab+含铂双药化疗（PDCT） vs. 纳武利尤单抗+PDCT，作为IV期或复发性NSCLC的一线治疗

LBA53 - Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase 2 RELATIVITY-104 study

讲者：Nicolas Girard (Paris, France)

讲座时间：2024.9.14 08:40 - 08:50

摘要号及标题：

LBA54 - MARIPOSA-2研究的第二次期中OS分析：Amivantamab联合化疗 vs. 单纯化疗在奥希替尼治疗后疾病进展的EGFR突变晚期NSCLC中疗效

LBA54 - Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated, Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib: 2nd Interim Overall Survival From MARIPOSA-2

讲者：Sanjay Popat (London, United Kingdom)

讲座时间：2024.9.14 09:10 - 09:20

摘要号及标题：

LBA57 - KRYSTAL-12研究：Adagrasib（ADA）vs. 多西他赛（DOCE）治疗KRAS G12C突变晚期NSCLC和基线脑转移患者

LBA57 - Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): results from KRYSTAL-12

讲者：Fabrice Barlesi (Villejuif, France, CEDEX 20)

讲座时间：2024.9.14 11:20 - 11:25